Policy & Regulation
Ascletis reports Phase II weight‑loss results for ASC30 depot formulation
...
NS Pharma and NCNP report 4.5-year brogidirsen data for DMD treatment
10 March 2026 - NS Pharma Inc, a subsidiary of Japan-based Nippon Shinyaku Co Ltd (TYO:4516), announced on Monday that the National Center of Neurology and Psychiatry (NCNP) has presented 4.5-year saf...
Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment
...
Koselugo approved in Canada for adults with NF1 and inoperable plexiform neurofibromas
...
Bristol Myers Squibb reports positive Phase 3 results for oral mezigdomide in multiple myeloma
9 March 2026 - Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with...
Pfizer reports positive Phase 2 results for trispecific antibody in atopic dermatitis
9 March 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Monday reported positive topline results from a Phase 2 study evaluating tilrekimig (PF-07275315) in adults with moderate to severe...